Company | BioCryst Pharmaceuticals |
Stock Quote | NASDAQ: BCRX |
Study Name | ORLADEYO (berotralstat) |
Treatment | Hereditary angioedema (HAE) |
Status | New Drug Application (NDA) |
Catalyst Date | September 12, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Cytokinetics |
Stock Quote | NASDAQ: CYTK |
Study Name | Aficamten |
Treatment | Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) |
Status | Phase 3 |
Catalyst Date | September 26, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Unicycive Therapeutics |
Stock Quote | NASDAQ: UNCY |
Study Name | Oxylanthanum Carbonate (OLC) |
Treatment | Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) |
Status | Phase 1 |
Catalyst Date | June 28, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Jazz Pharmaceuticals |
Stock Quote | NASDAQ: JAZZ |
Study Name | Zepzelca (lurbinectedin) |
Treatment | Relapsed Small Cell Lung Cancer (SCLC) |
Status | Phase 3 |
Catalyst Date | October 7, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Arcutis Biotherapeutics |
Stock Quote | NASDAQ: ARQT |
Study Name | ZORYVE™ (roflumilast) |
Treatment | Inhibitor of phosphodiesterase-4 (PDE4) |
Status | supplemental New Drug Application (sNDA) |
Catalyst Date | October 13, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Syndax Pharmaceuticals |
Stock Quote | NASDAQ: SNDX |
Study Name | Revumenib |
Treatment | Relapsed/Refractory KMT2Ar Acute Leukemia |
Status | supplemental New Drug Application (sNDA) |
Catalyst Date | October 25, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Merck |
Stock Quote | NYSE: MRK |
Study Name | sotatercept-csrk |
Treatment | In adults with pulmonary arterial hypertension |
Status | Biologics License Applications (BLA) Priority Review |
Catalyst Date | October 25, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | REGENXBIO |
Stock Quote | NASDAQ: RGNX |
Study Name | RGX-121 |
Treatment | MPS II (Hunter Syndrome) |
Status | Biologics License Applications (BLA) |
Catalyst Date | November 9, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Ascendis Pharma |
Stock Quote | NASDAQ: ASND |
Study Name | TransCon CNP |
Treatment | In Children with Achondroplasia |
Status | New Drug Application (NDA) |
Catalyst Date | November 30, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Kura Oncology |
Stock Quote | NASDAQ: KURA |
Study Name | Ziftomenib |
Treatment | Treatment of genetically defined AML patients with high unmet need |
Status | New Drug Application (NDA) |
Catalyst Date | November 30, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Bristol-Myers Squibb |
Stock Quote | NYSE: BMY |
Study Name | Breyanzi (lisocabtagene maraleucel) |
Treatment | Second-line treatment in adults with relapsed or refractory large B-cell lymphoma (LBCL) |
Status | supplemental Biologics License Applications (sBLA) |
Catalyst Date | December 5, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Milestone Pharmaceuticals |
Stock Quote | NASDAQ: MIST |
Study Name | Etripamil |
Treatment | For Treatment in Paroxysmal Supraventricular Tachycardia |
Status | N/A |
Catalyst Date | December 13, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Innoviva |
Stock Quote | NASDAQ: INVA |
Study Name | Zoliflodacin |
Treatment | For the Treatment of Uncomplicated Gonorrhea |
Status | Phase 3 |
Catalyst Date | December 15, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Aldeyra Therapeutics |
Stock Quote | NASDAQ: ALDX |
Study Name | Reproxalap |
Treatment | Small-molecule modulator of RASP |
Status | New Drug Application (NDA) |
Catalyst Date | December 16, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Cytokinetics |
Stock Quote | NASDAQ: CYTK |
Study Name | Aficamten |
Treatment | Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) |
Status | New Drug Application (NDA) |
Catalyst Date | December 26, 2025 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Denali Therapeutics |
Stock Quote | NASDAQ: DNLI |
Study Name | tividenofusp |
Treatment | For the treatment of Hunter syndrome (MPS II) |
Status | Biologics License Applications (BLA) |
Catalyst Date | January 5, 2026 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Atara Biotherapeutics |
Stock Quote | NASDAQ: ATRA |
Study Name | Tabelecleucel (tab-cel) |
Treatment | Post-Transplant Lymphoproliferative Disease (PTLD) |
Status | Biologics License Applications (BLA) |
Catalyst Date | January 10, 2026 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Aquestive Therapeutics |
Stock Quote | NASDAQ: AQST |
Study Name | Anaphylm |
Treatment | For epinephrine prodrug candidate product |
Status | New Drug Application (NDA) |
Catalyst Date | January 31, 2026 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Vanda Pharmaceuticals |
Stock Quote | NASDAQ: VNDA |
Study Name | Bysanti |
Treatment | For the Treatments of Acute Bipolar I Disorder and Schizophrenia |
Status | New Drug Application (NDA) |
Catalyst Date | February 21, 2026 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Eton Pharmaceuticals |
Stock Quote | NASDAQ: ETON |
Study Name | ET-600 |
Treatment | For the treatment of an endocrinology |
Status | New Drug Application (NDA) |
Catalyst Date | February 25, 2026 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Bristol-Myers Squibb |
Stock Quote | NYSE: BMY |
Study Name | Deucravacitinib |
Treatment | Moderate to severe plaque psoriasis |
Status | supplemental New Drug Application (sNDA) |
Catalyst Date | March 6, 2026 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Lantheus |
Stock Quote | NASDAQ: LNTH |
Study Name | Piflufolastat F 18 (formerly 8F-DCFPyL) |
Treatment | Biochemically Recurrent Prostate Cancer (CONDOR) |
Status | New Drug Application (NDA) |
Catalyst Date | March 6, 2026 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Company | Arvinas |
Stock Quote | NASDAQ: ARVN |
Study Name | Vepdegestrant |
Treatment | For ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. |
Status | New Drug Application (NDA) |
Catalyst Date | June 5, 2026 |
Catalyst | PDUFA Date |
Announcement | Read More |
Website | Click Here |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE